Last update 20 Oct 2025

gMSC 1(Two Cells)

Overview

Basic Info

Drug Type
Mesenchymal stem cell therapy
Synonyms
gMSC1
Target-
Action-
Mechanism
Cartilage replacements
Therapeutic Areas
Skin and Musculoskeletal DiseasesOther DiseasesImmune System Diseases
Active Indication
Cartilage InjuryOsteochondritis DissecansIntervertebral Disc Disease+ [3]
Inactive Indication-
Originator Organization
Two Cells Co., Ltd.Two Cells Co., Ltd.
Active Organization
Two Cells Co., Ltd.Two Cells Co., Ltd.
Inactive Organization
Chugai Pharmaceutical Co., Ltd.Chugai Pharmaceutical Co., Ltd.
License Organization
Two Cells Co., Ltd.Two Cells Co., Ltd.Kaken Pharmaceutical Co., Ltd.Kaken Pharmaceutical Co., Ltd.
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with gMSC 1(Two Cells)
JPRN-jRCT1080223548
/ CompletedPhase 3
A Randomized, Open-Label, Controlled, Phase III Trial Comparing guaranteed Mesenchymal Stem Cell 1 (gMSC1) versus Microfracture (MFx) in Patients with Symptomatic Articular Cartilage Defects or Osteochondritis Dissecans in the Knee
100 Clinical Results associated with gMSC 1(Two Cells)
Login to view more data
100 Translational Medicine associated with gMSC 1(Two Cells)
Login to view more data
100 Patents (Medical) associated with gMSC 1(Two Cells)
Login to view more data
1
Literatures (Medical) associated with gMSC 1(Two Cells)
01 Oct 2024CYTOTECHNOLOGY
Correction: Development of scaffold-free tissue-engineered constructs derived from mesenchymal stem cells with serum-free media for cartilage repair and long-term preservation
100 Deals associated with gMSC 1(Two Cells)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cartilage InjuryPhase 3
Japan
Two Cells Co., Ltd.Two Cells Co., Ltd.
31 Oct 2017
Osteochondritis DissecansPhase 3
Japan
Two Cells Co., Ltd.Two Cells Co., Ltd.
31 Oct 2017
Intervertebral Disc DiseasePreclinical
Japan
Two Cells Co., Ltd.Two Cells Co., Ltd.
01 Feb 2025
Ligament injuryPreclinical
Japan
Two Cells Co., Ltd.Two Cells Co., Ltd.
01 Feb 2025
Meniscus disorderPreclinical
Japan
Two Cells Co., Ltd.Two Cells Co., Ltd.
01 Feb 2025
Osteoarthritis, KneePreclinical
Japan
Two Cells Co., Ltd.Two Cells Co., Ltd.
01 Feb 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free